News Novartis buys into bispecific antibodies with Xencor deal Agreement could add to Novartis' immuno-oncology pipeline.
News Novartis cancer drugs among raft of NICE recommendations NICE recommends funding for lung cancer and skin cancer treatments.
News Novartis to split pharmaceuticals division in two, Epstein t... Following its $20 billion asset swap with GlaxoSmithKline last year, Novartis is to split its pharmaceutical division in two, creating two business units, with the former single business un
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
